Abstract:HsDHODH is a target of the human dehydrogenase enzyme, and HsDHODH inhibitors have shown potential applications in treating autoimmune diseases and cancer. Specific inhibitors have demonstrated potential therapeutic efficacy in treating autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. However, the use of HsDHODH inhibitors may cause some side effects, such as interfering with DNA synthesis and causing apoptosis, which can be harmful to the body. In addition, drug resistance may occur during their use. Furthermore, the pharmacological mechanism of action of HsDHODH inhibitors is not fully understood, which may limit their use in treating specific diseases. Recently, the ASGBIE_ESS method was used to calculate the binding free energy between HsDHODH and ascofuranone derivatives. The results showed a correlation of 0.9066 with experimental data, indicating the method's reliability. The energy decomposition analysis identified several hot-spot residues, including M13, L16, Q17, H26, F32, F68, R106, Y326, and T330, that play crucial roles in the ligand-protein binding process based on the crystal structure. Combining virtual screening with the ASGBIE_ESS method, new compounds with unique backbones that have the potential to be valuable inhibitors of HsDHODH were identified. Remarkably, the computational predictions for the biological activity of these derivatives exceeded experimental results. The analysis showed that the identified compounds form stable hydrophobic interactions with residues around the pocket in the protein's hydrophobic region. Additionally, the binding ability of these derivatives is improved when they form hydrogen bonding interactions with specific residues in the pocket. In conclusion, this study provides valuable insights into the mechanism of ligand-protein binding for HsDHODH and offers promising leads for developing novel inhibitors targeting this enzyme.

Discovery and Optimization of Novel <i>h</i>DHODH Inhibitors for the Treatment of Inflammatory Bowel Disease

Discovery and Optimization of Novel h DHODH Inhibitors for the Treatment of Inflammatory Bowel Disease

Discovery a Series of Novel Inhibitors of Human Dihydroorotate Dehydrogenase: Biological Activity Evaluation and Molecular Docking.

Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor γ-t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease

Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor -t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease

Discovery of a Novel Series of Hdhodh Inhibitors with Anti-Pulmonary Fibrotic Activities.

Discovery of Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on a Benzophenone Scaffold

A Novel Series of Human Dihydroorotate Dehydrogenase Inhibitors Discovered by in Vitro Screening: Inhibition Activity and Crystallographic Binding Mode

Design, Synthesis, X-ray Crystallographic Analysis, and Biological Evaluation of Thiazole Derivatives As Potent and Selective Inhibitors of Human Dihydroorotate Dehydrogenase.

Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods

Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment

[F01WB-1315 A and B, Two Dihydroorotate Dehydrogenase Inhibitors from Microbial Metabolites].

Identification of Mechanism of Action and Novel Compounds Targeting HsDHODH: Insights from Computational Analysis

Biological Evaluation of Quinoline Derivatives As Inhibitors of Human Dihydroorotate Dehydrogenase

Structural Optimization and Structure–Activity Relationship of 4-Thiazolidinone Derivatives As Novel Inhibitors of Human Dihydroorotate Dehydrogenase

Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives As Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.

Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents

[Design, Synthesis and Structure-Activity Relationship Studies of Human Dihydroorotate Dehydrogenase Inhibitors].

Development of a Human Dihydroorotate Dehydrogenase (hdhodh) Pharma-Similarity Index Approach with Scaffold-Hopping Strategy for the Design of Novel Potential Inhibitors.

A Novel Series of Teriflunomide Derivatives As Orally Active Inhibitors of Human Dihydroorotate Dehydrogenase for the Treatment of Colorectal Carcinoma

Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives As Highly Potent P2Y14 Receptor Antagonists for Inflammatory Bowel Disease Treatment